The DOI matches its Crossref record; 301 of the 301 references it cites were found in a registry or an index; 179 of the 258 sources its claims cite were checked for support.
Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword
Open accessAbstract
Multiple myeloma (MM) is a hematological malignancy defined by the abnormal proliferation and accumulation of plasma cells (PC) within the bone marrow (BM). While multiple myeloma impacts the bone, it is not classified as a primary bone cancer. The bone marrow microenvironment significantly influences the progression of myeloma and its treatment response. Mesenchymal stromal cells (MSCs) in this environment engage with myeloma cells and other bone marrow components via direct contact and the secretion of soluble factors. This review examines the established roles of MSCs in multiple facets of MM pathology, encompassing their pro-inflammatory functions, contributions to tumor epigenetics, effects on immune checkpoint inhibitors (ICIs), influence on reprogramming, chemotherapy resistance, and senescence. This review investigates the role of MSCs in the development and progression of MM.
Overview
CoChat Summary
## TL;DR
This is a review of how mesenchymal stromal cells (MSCs) in the bone marrow niche can both support and restrain multiple myeloma (MM), with emphasis on tumor promotion, immune evasion, drug resistance, epigenetic change, and senescence. The authors argue that MSC-targeted strategies may be useful, but only with careful attention to MSC heterogeneity, safety, and the tumor microenvironment.
## Key findings
- MM cells and bone marrow MSCs interact through direct contact and soluble factors, and this bidirectional crosstalk reshapes MSCs into MM-supportive cells with altered gene expression, epigenetic changes, senescence, and reprogramming.
- MSCs contribute to MM progression through pro-inflammatory signaling, immune suppression, immune checkpoint pathways, angiogenesis, and chemoresistance; the review specifically highlights IL-6, VEGF, TGF-β, NF-κB, PI3K/AKT, and MAPK signaling.
- The paper cites a study in which hypoxic bone marrow stromal cell-derived extracellular vesicles carried increased miR-140-5p and miR-28-3p and reduced bortezomib sensitivity in MM cells by targeting SPRED1 and increasing MAPK signaling.
- It also cites a murine study where the dual inhibitor CM-272 prevented tumor-associated bone loss and reduced tumor burden in a myeloma model, and notes that iMSC signature expression correlated positively with minimal residual disease.
## Methods
- This is a narrative review, not an original experimental study.
- The authors report a comprehensive literature search of PubMed, Scopus, Web of Science, and Google Scholar from database inception to March 2024, using the keywords “Multiple myeloma,” “Bone marrow mesenchymal stromal cells,” and “Myeloma progression.”
- Included studies were original English-language reports on MSC roles in MM pathology; conference abstracts, case reports, non-English papers, case series, and letters were excluded. Two researchers screened the literature independently and resolved disagreements by negotiation.
## Limitations
- The paper states that many critical research areas remain insufficiently investigated, including MSC heterogeneity in the bone marrow niche, temporal evolution of MSC changes, and the roles of non-coding RNAs and extracellular vesicles.
- It also notes that future work should use single-cell RNA sequencing, spatial transcriptomics, and longitudinal epigenetic profiling, implying that current evidence is limited by incomplete resolution of MSC subtypes and their spatial/temporal dynamics.
- Evident from the text: because this is a review, it does not present new primary data, effect sizes, or a single unified meta-analytic estimate; conclusions depend on heterogeneous prior studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
123 Valid · 23 Not valid · 45 Not checked · 46 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, investigations demonstrate the importance of exosomal miR-483-5p produced from BM-MSCs in stimulating the tumor suppressor gene TIMP2 to advance the malignant development of MM [270].”
§ Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword > Methods > Mesenchymal stromal cells and the senescence of MM
What the sources say
- Disputedcites [270] Gu J, et al. Exosomal miR-483-5p in bone marrow mesenchymal stem cells promotes malignant progression of multiple myeloma by targeting TIMP2. Front Cell Dev Biol. 2022;10:862524. sourceExperimental — accuracy not yet measured
The Discussion says exosomal miR-483-5p from MM-MSCs favors multiple myeloma progression, but it does not stimulate TIMP2. The Results section “TIMP2 Is the Target of miR-483-5p” reports that miR-483-5p decreases TIMP2 mRNA and protein expression—the opposite of the claimed mechanism. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“MSCs can develop into adipocytes, but myeloma cells prevent them from doing so [279].”
§ Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword > Methods > Reprogramming of mesenchymal stromal cells in MM Many strategies for treating MM bone disease have been discovered recently, particularly in relation to the utilization of MSCs [271]. One of the uses of MSCs is to use them to produce iPSC [272, 273]. Studies have shown that MSCs are more efficient in reprogramming compared to other somatic cells [274, 275]. Osteoblasts, which are derived from MSCs, are in charge of the development of new bone. According to reports, myeloma cells prevent MSCs from differentiating into mature osteoblasts [42, 276, 277]. In fact, lineage plasticity is exhibited by osteoblasts and adipocytes, which share a common progenitor that is produced from MSCs [278]. One feature of MM is the suppression of bone formation. MSCs can develop into adipocytes, but myeloma cells prevent them from doing so [279]. BM adipocytes are now understood to be more than merely inert “filler cells”; they are significant regulators of bone remodeling [280, 281]. According to Liu et al.‘s study, myeloma cells have the capacity to reprogram normal BM adipocytes, giving them the capacity to resorb bone in myeloma patients who are in remission [282, 283]. Lemaitre et al. conducted a study with the aim of determining whether MM-MSCs also contribute to disease recurrence. Ultimately, they discovered that changes, possibly brought about by epigenetic reprogramming, caused by the presence of MM PC in the BM caused the MSC to change into a persistent pro-tumoral phenotype. Furthermore, they proposed that MSC can contribute to the recurrence of MM by encouraging the development of minimal residual cells [284]. Recent studieshave shown that myeloma-induced bone disease is influenced by bone marrow adipocytes (BMAds) and that BMAds that have undergone MM-reprogramming are a part of this process. MM-MSCs also exhibit decreased osteogenic potential and changes in the expression of transcripts related to the pathophysiology of MM illness (IL-6). There is evidence that MM-MSCs have abnormal secretory profiles and senescent traits that might hinder bone production [221, 285, 286]. After the MM niche has stabilized, when stromal, endothelial, or osteolineage cells come into direct touch with malignant PC, the immediate BM microenvironment is reprogrammed, either leading to the facilitation of immune escape and the activation of cytokines that promote MM cells [287, 288]. These reactions provide MM cells additional signals for growth, and as a result, a favorable TME is generated as they progressively become independent of the initial support of their typical habitat. Notably, MM-MSCs have different gene profiles from their counterparts in normal MSCs [289, 290]. Moreover, as previously indicated, MM cells may now function remotely to create new premetastatic niches for tumor spread in other bone areas by secreting growth factors, cytokines, and exosomes that alter the ECM in these new locations [291]. The multiline age differentiation potential of BMSCs is contingent upon their growth status and their interactions with their microenvironment in both healthy and diseased states. This is because BMSCs are pluripotent progenitor cells that possess the ability to self-renew and the potential to differentiate into multiple mesoderm lineage cells, such as chondrocytes, adipocytes, and osteoblasts [292–294]. For example, normal epigenetic reprogramming and differentiation capabilities of BMSCs into functional osteoblasts are disrupted throughout aging and in a variety of inflammatory and malignant situations, leading to increased adipogenesis and decreased osteogenesis [295]. Since The majority of people with MM are old, with a typical diagnosis age of about 70 years, The remarkable parallels between the alterations seen in BMSCs from elderly persons and those found in BMSCs from pathologic inflammatory diseases affecting the BM should not be overlooked [296].
What the sources say
- Disputedcites [279] Liu Z et al. Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells. Sci Signal, 2020. 13(633). sourceExperimental — accuracy not yet measured
The Results section, “Myeloma cells enhance adipogenesis and reduce osteoblastogenesis from MSCs” (page not provided), says myeloma cells directed MSC differentiation preferentially toward adipocytes. The claim reverses that finding: the paper reports that myeloma cells promote, rather than prevent, adipocyte development. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In multiple myeloma, mesenchymal stem cells (MSCs) play a role in the development of osteolytic bone lesions by promoting osteoclastogenesis [4].”
§ Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword > Introduction
What the sources say
- Partly supportedcites [4] Bishop RT, et al. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease. Nat Commun. 2024;15(1):2458. sourceExperimental — accuracy not yet measured
The introduction (page unavailable) says myeloma-derived factors stimulate osteoblast-lineage cells to recruit and activate osteoclasts through RANKL, contributing to excessive bone destruction. The paper identifies MSCs as precursors of osteoblast-lineage cells, but does not specifically say that MSCs themselves promote osteoclastogenesis or thereby cause osteolytic lesions. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, new research has shown that the WNT pathway directly alters cellular metabolism in OB lineage cells by promoting Gln catabolism, fatty acid oxidation, and aerobic glycolysis [48].”
§ Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword > Methods > Metabolism in the bone microenvironment cells The specialized cells known as osteoblasts (OBs) are involved in the process of bone production, while osteoclasts (OCs) are responsible for the resorption process. Bone remodeling mechanisms become uncoupled in MM, leading to the development of osteolytic bone lesions. An increase in osteoclastic formation and a decrease in osteoblastic formation describe altered bone remodeling [42, 43]. In fact, both the modeling and remodeling processes necessitate the manufacture of collagen and other matrix proteins by osteoblasts (OBs), thereby consuming a substantial quantity of energy in the form of adenosine triphosphate (ATP) [44, 45]. Given this, it is not unexpected that changes in the metabolite availability in the MM microenvironment produce modifications in the energy metabolism of bone cells, which in turn affect their development and function [46, 47]. Furthermore, new research has shown that the WNT pathway directly alters cellular metabolism in OB lineage cells by promoting Gln catabolism, fatty acid oxidation, and aerobic glycolysis [48]. In other words, cancer cells primarily use glucose, fatty acids, and amino acids to meet their biosynthetic needs [49–52]. Glucose is one of the most important fuel substrates for OBs. It enters cells through glucose transporters (GLUTs) through facilitated diffusion, an energy-free mechanism [53]. The main glucose transporter in OBs seems to be glucose transporter 1 (GLUT1), which is encoded by SLC2A1. However, GLUT3 and GLUT4 are also expressed [54]. As stated, before that OBs and their progenitors experience extensive energy reprogramming throughout the differentiation process. Research by Guntur et al. demonstrated that oxidative phosphorylation is the preferable method following the start of differentiation and matrix synthesis, but glycolysis is the primary means by which OB progenitors in mice produce ATP. Once mineralization is complete, mature OBs lean towards glycolysis. In line with these findings, metabolic tracing investigations demonstrated that the majority of glucose in mature OBs is converted to lactate and that glycolysis is the primary mechanism for ATP generation [55–57]. Tumor cells exhibit metabolic reprogramming, referred to as the Warburg Effect, which is believed to facilitate the production of amino acids, nucleotides, and lipids required for cell division. Moreover, the augmentation of aerobic glycolysis could aid in the mitigation of reactive oxygen species and additionally facilitate the production of a greater quantity of amino acids to support protein synthesis in osteoblasts [58]. Finally, glucose transport and metabolism could potentially be affected by the anti-MM medicines that are now being utilized. According to reports, when MM cells are treated with vincristine or the proteasome inhibitor bortezomib, the expression of GLUT1 and HK2 (Hexokinase 2) is reduced, leading to apoptosis [59]. OBs can utilize amino acids for the process of protein synthesis, or alternatively, they can undergo metabolism to produce ATP, which serves as a source of energy [60]. Glutamine (Gln), a nonessential amino acid (NEAA), is primarily produced by the enzyme Gln synthetase (GS) using glutamate (Glu) and ammonia (NH3) as substrates. It has been recognized as a significant regulator of osteoblasts due to the increased demand for amino acids resulting from the augmented synthesis of the bone matrix during bone formation [61]. Gln is transported into the cells through plasma-membrane Gln transporters, specifically SLC1A5 (ASCT2), SLC7A7, and SLC38A2 (SNAT2) [46, 62]. During the differentiation process of BM stromal cells (BMSCs) into osteoblasts, a significant amount of Gln is consumed. However, this consumption of Gln does not occur when BMSCs convert into adipocytes. According to reports, Gln enhances the activity of GLS (glutaminase) and GDH (Glutamate dehydrogenase) through the mTOR/S6 and MAPK signaling pathways, therefore stimulating cell proliferation [63]. Due to the rapid proliferation of OB progenitors into mature OBs capable of synthesizing bone matrix, the differentiation process is marked by a heightened use of Gln. It has been observed that when osteoblasts are induced to undergo mineralization, glucose alone is inadequate to fulfill their energy needs. The degree of mineralization only increases when cells are provided with glucose and glutamine supplementation [64, 65]. Many studies have shown that OBs and progenitors use different amino acids such as proline, methionine, arginine and tryptophan in their metabolism to support anabolic functions during bone formation and mineralization [49]. Recent investigations have shown that MM cells restrict the formation of osteoblasts by impeding the synthesis of asparagine in mesenchymal cells through the depletion of glutamine. This provides a metabolic explanation for the suppression of osteoblasts in MM. Ultimately, the metabolic characteristics of malignant plasma cells result in the creation of a bone marrow microenvironment that is distinguished by low amounts of Gln and high levels of Glu. This leads to a decrease in the development of osteoblasts and an increase in the differentiation of osteoclasts. Hence, directing attention towards the Gln glutamate axis may serve as an innovative therapeutic strategy for bone disease in patients with multiple myeloma [66].
What the sources say
- Supportedcites [48] Dirckx N, et al. The role of osteoblasts in energy homeostasis. Nat Reviews Endocrinol. 2019;15(11):651–65. source
The Amino acids section reports that Wnt3a stimulation increases aerobic glycolysis and glutamine consumption during osteoblast differentiation. The Fatty acids section reports that Wnt signalling regulates fatty acid catabolism in osteoblasts, while the Glucose section describes Wnt-enhanced aerobic glycolysis in osteoprogenitor-like cells. Page numbers were not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, MSCs have demonstrated the ability to mediate resistance to chemotherapy and other treatments, thereby complicating therapeutic strategies [8, 9].”
§ Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword > Introduction
What the sources say
- Partly supportedcites [8] Minev T, et al. Mesenchymal stem cells - the secret agents of cancer immunotherapy: promises, challenges, and surprising twists. Oncotarget. 2024;15:793–805. sourceExperimental — accuracy not yet measured
The sections on MSC-induced immunosuppression and tumor growth promotion say MSCs can protect tumors and complicate cancer therapy. However, the Introduction attributes resistance to chemotherapy and other conventional treatments to cancer biology, not to MSCs; our copy does not establish MSC-mediated treatment resistance. (LLM, conf=0.82)
- Partly supportedcites [9] Afkhami H, et al. New insights in application of mesenchymal stem cells therapy in tumor microenvironment: pros and cons. Front Cell Dev Biology. 2023;11:1255697. sourceExperimental — accuracy not yet measured
In “Immunosuppression and tumorigenesis features of MSCs” (page unavailable), the paper reports that MSCs can have chemoprotective effects and that MSC-derived cancer-associated fibroblasts aid drug resistance. These passages support resistance to chemotherapy, but do not establish resistance to other kinds of treatment. (LLM, conf=0.84)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
98 more claims · 57 with their cited sources checked
Create a free account to see all 237 claims and to verify the 18 references still open.
- It may state two separate claims as one. 110
- Probably not a substantial claim. 35
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Functions and mechanisms of non-histone protein acetylation
Narita, T., Weinert, B. T., & Choudhary, C. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0081-3 · Cited by 1,232 · cited 1×
“The lysine acetylation forward and backward processes are catalyzed, respectively, by histone acetyltransferase [110] and histone deacetylases (HDACs) [147].”
Glutamine reliance in cell metabolism
Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021 · cited 1×
“It has been recognized as a significant regulator of osteoblasts due to the increased demand for amino acids resulting from the augmented synthesis of the bone matrix during bone formation [61].”
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001 · cited 1×
“In this study, they investigated the effect of Nivolumab but did not show any tumor response in relapsed/refractory MM [207].”
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential
Song, N., Scholtemeijer, M., & Shah, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.009 · Cited by 948
Mesenchymal stem cells: a new trend for cell therapy
Wei, X., Yang, X., Han, Z.-P., Qu, F.-F., Shao, L., & Shi, Y.-F. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.50 · Cited by 942 · cited 1×
“This is because BMSCs are pluripotent progenitor cells that possess the ability to self-renew and the potential to differentiate into multiple mesoderm lineage cells, such as chondrocytes, adipocytes, and osteoblasts [292–294].”
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · cited 1×
“The activation of NF-KB, which is the outcome of the VLA4-VCAM1 molecule in MM cells and MSCs, stimulates the transcription and release of the primary MM cell growth molecule, IL-6 [102].”
Research works printed but not linked: 11
- García-Sánchez D et al. Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression. 2023. 15(5): p. 421. · DOI · Paper page
- Giuliani N, Mangoni M, Rizzoli VJEh. Osteogenic Differ Mesenchymal Stem Cells Multiple Myeloma: Identif Potential Therapeutic Targets. 2009;37(8):879–86.
- Cippitelli M et al. Role of NF-κB signaling in the interplay between multiple myeloma and mesenchymal stromal cells. Int J Mol Sci, 2023. 24(3). · DOI · Paper page
- Dinmukhamedova AS, et al. Morphofunctional, hematological and biochemical indicators of First-Year students who came to study from urban and rural areas. Clin Schizophrenia Relat Psychoses. 2021;15(3):130521–130521.
- Khaniki MAL, Mirzaeibonehkhater M, Manthouri M. Enhancing Pneumonia Detection using Vision Transformer with Dynamic Mapping Re-Attention Mechanism. in 2023 13th International Conference on Computer and Knowledge Engineering (ICCKE). 2023.
- Hatami S, et al. The role of human Platelet-rich plasma in burn injury patients: A single center study. Canon J Med. 2023;4(2):41–5.
- Hatami S, et al. Evaluation the effect of lipofilling in burn Scar: A cross-sectional study. Canon J Med. 2023;4(3):78–82.
- Liu Z, et al. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12(1):99. · DOI · Paper page
- Kanehira M, et al. An lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma. Stem Cells. 2017;35(3):739–53. · DOI · Paper page
- Fairfield H, et al. Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2021;10:584683. · DOI · Paper page
- Liu H et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med, 2019. 11(494). · DOI · Paper page
Cited by
Role of Nuclear Receptors on the Progression of Multiple Sclerosis: A Review
Babaalizadeh, B., Kalaki-Jouybari, F., Kahaki, F. A., Afkhami, H., & Razavi, Z.-S. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01563-z · Cited by 7
“In BALBcByJ mice, RXRγ-/-KO mice exhibit memory loss and depressive behavior (Wietrzych-Schindler et al. 2011; Kamrani et al. 2025).”
Self-citationLessons Learned from Liver-on-Chip Platform
Razavi, Z. S., Razavi, F. S., Soltani, M., Pazoki–Toroudi, H., Farokhi, S., Azimi, I., & Ahmadi, N. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03779-y · Cited by 9
“[ 121 –124 ] L i v e r c h i p b a s e d on 3 D b i op r i n ti ng T i m e - e ffi c i e n t a nd h i gh - t h r oughpu t m e t hod f o r c on s t r u c ti ng c o m p l e x 3 D b i o l og i ca l m i c r o s ca l e s t r u c t u r e s u s i ng a w i d e r a ng e o f ce ll t yp e s a nd b i o m a t e…”
Self-citationLi, D.-Q., Zheng, X., Lin, D., Cheng, Y., Wang, Z., Chen, Y., & Xie, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1766460 · Cited by 12
“In addition, BMSCs play a dual role in bone regeneration and immune regulation, and their phenotypic changes may further affect bone immune homeostasis, providing a basis for potential intervention targets (43).”
miR-429 Acts as a Tumor Suppressor in Multiple Myeloma by Regulating Cell Proliferation
Abdelkarim, M., Limam, I., Berred, E., et al. (2025) · Hemato · doi:10.3390/hemato6030030 · Cited by 4
“These findings justify our investigation of miR-429 not only in malignant plasma cells but also within the stromal compartment [8,9]. miR-429, a member of the miR-200 family, has been reported to play dual, context-dependent roles in various cancers.”
Nasso, M. E., Bottaro, A., Fazio, M., Stagno, F., Gangemi, S., & Allegra, A. (2026) · Biomolecules · doi:10.3390/biom16050710 · Cited by 3
Metadata
- Authors
- Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H.
- Affiliations
- Guilan University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
- Iran University of Medical Sciences (IR)
- Shahed University (IR)
- Fasa University of Medical Sciences (IR)
- Shahrekord University of Medical Sciences (IR)
- Tarbiat Modares University (IR)
- Corresponding author
- Saeidi, Farzane
- Ronaghi, Hossein
- Venue
- Cancer Cell International
- Published
- 2025-03-26
- Volume
- 25
- Issue
- 1
- Pages
- 117-117
- ISSN
- 1475-2867 (ISSN-L)
- PMC
- PMC11948648
- OpenAlex
- W4408851711
- Semantic Scholar
- d10b82687ae82913acd296cad665a04dbfe06914
- Cited by
- 27
- References
- 298
- Citations by year
- 2026: 19 · 2025: 8
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Cell International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- multiple myeloma, mesenchymal stem cells, bone marrow microenvironment, plasma cells, cancer epigenetics, immune checkpoint inhibitors, chemoresistance, cellular senescence, tumor reprogramming, myeloma progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword. https://app.cochat.ai/papers/10.1186/s12935-025-03741-x
- The paper
- Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025). Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword. Cancer Cell International. https://doi.org/10.1186/s12935-025-03741-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.